What question did this study set out to answer?

This research aims to evaluate local control outcomes and identify predictors of local progression following stereotactic ablative radiotherapy in oligometastatic cancer patients.

June 11, 2026Open Access

Local control in oligometastatic cancer patients following metastasis-directed stereotactic ablative radiotherapy: An interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohort.

Puntos clave

This research aims to evaluate local control outcomes and identify predictors of local progression following stereotactic ablative radiotherapy in oligometastatic cancer patients.
Prospective observational registry (EORTC-ESTRO E2-RADIatE) evaluating SABR for various cancers in oligometastatic patients.
Includes 2,447 patients from 57 institutions who followed the recommended treatment protocol with a median follow-up of 31 months.
Multivariate analyses at patient and lesion levels to account for confounding factors.
The 1- and 3-year local progression rates were 5.0% and 11.4%, respectively.
Higher PTV minimum dose predicted improved local control (11% risk reduction per 10 Gy EQD2 increase, HR 0.89 [97.5% CI 0.82-0.98], p = 0.005).
Colorectal cancer showed a higher risk of progression compared to prostate cancer (HR 2.63 [97.5% CI 1.71-4.05], p < 0.001).

Resumen

Aim To evaluate real-world local control outcomes and identify clinical and dosimetric determinants of local progression following metastasis-directed stereotactic ablative radiotherapy (SABR) within the international OligoCare cohort. Methods OligoCare is a prospective observational registry (EORTC-ESTRO E2-RADIatE) evaluating SABR for oligometastatic prostate, breast, colorectal, and non-small cell lung cancer (NSCLC). The secondary endpoint, local progression, was defined as recurrence within the planning target volume (PTV), with death treated as a competing risk. Multivariate analyses were performed at both the patient and lesions levels (restricted to single-lesion patients) to account for confounding factors. Results Between July 2019 and July 2025, 2,805 eligible patients were enrolled. Of these, 2,447 from 57 institutions received the recommended protocol treatment and were included in the analysis (median follow-up 31 months). The distribution of primary tumors was prostate (41.7%), NSCLC (21.7%), colorectal (21.2%), and breast (15.4%). The 1- and 3-year local progression rates were 5.0% and 11.4%, respectively. Among single-lesion patients (n = 1,714), a higher PTV minimum dose was the sole independent predictor of local control, with an 11% risk reduction per 10 Gy EQD2 increase (HR 0.89 97.5% CI 0.82-0.98, p = 0.005). Although de novo OMD showed better local control compared to repeat OMD in the patient-level analysis (HR0.65 97.5% CI 0.47-0.91, p = 0.004), this effect was largely driven by higher dose delivery in de novo cases. Colorectal primaries faced a significantly higher risk of progression than prostate cancer (HR 2.63 97.5% CI 1.71-4.05, p < 0.001), despite receiving the highest dose per fraction. Conclusion SABR provides durable real-world local control in oligometastatic disease. Optimizing the minimum PTV dose appears the most critical technical factor for success. The inferior local control observed in colorectal metastases suggests a combination of treatment intensity challenges and intrinsic radioresistance, which could guide future trial design and dose-escalation strategies.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo